Search | Clinical Trials Finder

Conditions: Hiv, HIV/AIDS, Disclosure
Interventions: Tough Talks Online, Tough Talks Clinic, Standard of Care; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 29 Years · Male only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Unsafe Sex, Risk Reduction
Interventions: PROJECT POWER, Power Health; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Diego, California + 12 more

Conditions: Sarcoma
Interventions: cilengitide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 3
States / cities: La Jolla, California • San Francisco, California • Nashville, Tennessee

Conditions: HIV Infections
Interventions: Cabenuva Scheduling Alerts in the Retention & Huddle modules of the CHORUS App; Other
Lead sponsor: Epividian; Industry
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 3
States / cities: Aurora, Colorado • Chicago, Illinois • Cleveland, Ohio

Conditions: HIV, HIV Testing, Women, Contingency Management
Interventions: Standard referral for HIV testing, Online risk reduction training, Reinforcement; Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: HIV/AIDS
Interventions: BCAP peer-driven intervention (PDI), Control intervention; Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 3,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Efavirenz; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 42
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 33 more

Conditions: Hiv, Violence
Interventions: WMR; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV-1 Infection
Interventions: DOR/ISL; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Baltimore, Maryland + 1 more

Conditions: HIV Infections
Interventions: iPrEP, Usual Care; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Donors, HIV Positive
Interventions: collection of follow-up sample based on PRISM HIV O Plus result; Device
Lead sponsor: Abbott Diagnostics Division; Industry
Eligibility: 17 Years and older
Enrollment: 24,111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Davenport, Iowa • Kansas City, Missouri • Dayton, Ohio + 4 more

Conditions: HIV, HBV (Hepatitis B Virus), HCV
Interventions: electronic medical record alert linked to orders; Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: SB-728mR-T, Cyclophosphamide; Genetic · Drug
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 5
States / cities: San Francisco, California • Norwalk, Connecticut • Orlando, Florida + 2 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir, Nelfinavir mesylate, Efavirenz, Nevirapine, Medroxyprogesterone acetate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 31
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 17 more

Conditions: HIV-1 Infection
Interventions: Cenicriviroc 100 mg, Cenicriviroc 200 mg + Truvada, Sustiva + Truvada; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more

Conditions: HIV-infection/AIDS
Interventions: Cultural adaptation of a patient-provider communication tool; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: e-HERO: Ending the HIV Epidemic in Rural Oklahoma; Behavioral
Lead sponsor: Northern Arizona University; Other
Eligibility: 17 Years to 29 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Flagstaff, Arizona

Conditions: HIV Infections
Interventions: Atazanavir/ Stavidine / Lamivudine, Atazanavir-Ritonavir/ Stavidine / Lamivudine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Call For Information, New Jersey

Conditions: Human Immunodeficiency Virus Infections
Interventions: lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 664 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 30
States / cities: Phoenix, Arizona • Beverly Hills, California • Fountain Valley, California + 23 more

Conditions: HIV Prevention, Pre-exposure Prophylaxis
Interventions: Individualized Feedback; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infection
Interventions: Placebo, Maraviroc; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: San Francisco, California • Stanford, California • Chicago, Illinois + 1 more

Conditions: HIV/AIDS, Myocardial Infarction
Interventions: Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men (YMSM)

Project Power: An HIV Risk Reduction Intervention for Black Men Who Have Sex With Men and Women (BMSM/W)

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma

Cabenuva Injection Tracking in CHORUS

Study of Anti-HIV Therapy Intensification

A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women

Peer-driven Intervention to Seek, Test & Treat Heterosexuals at High Risk for HIV

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Within My Reach (WMR) Adaptation

Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)

Leveraging the Emergency Department to Engage African American Women in HIV Pre-Exposure Prophylaxis

Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay

HIV/HBV/HCV Triple Screening in Primary Care

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus

WeExPAnd: PrEP Demonstration Project Among Women at Risk for HIV Infection - Preexposure Prophylaxis (PrEP)

e-HERO: Ending the HIV Epidemic in Rural Oklahoma

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects

Stick2PrEP Cisgender Women and Trans Individuals

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Inflammation and Cardiovascular Health in Women